Skip to main content
Journal cover image

Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment.

Publication ,  Journal Article
Weisler, RH; Ota, A; Tsuneyoshi, K; Perry, P; Weiller, E; Baker, RA; Sheehan, DV
Published in: J Affect Disord
November 1, 2016

BACKGROUND: Major depressive disorder (MDD) is a common, debilitating disorder with substantial socioeconomic burden. Many patients with MDD experience symptoms that impair functioning and productivity, often negatively affecting work or educational pursuits. This Phase 3b open-label study evaluated adjunctive brexpiprazole in young adults with MDD, who were in work or study. METHODS: Young patients (18-35 years) with MDD (inadequate responders to 1-3 antidepressant treatments [ADT] for their current episode) received brexpiprazole 1-3mg/day (target dose, 2mg/day) adjunctive to the same stable dose of ADT for 12 weeks. RESULTS: Depressive symptoms improved during treatment with adjunctive brexpiprazole (primary endpoint, least squares [LS] mean change from baseline in Montgomery-Åsberg Depression Rating Scale [MADRS] total score, -18.1 [p<0.0001]). Reductions from baseline in Sheehan Disability Scale Score (SDS; LS mean change -11.2 [p<0.0001]) and Work Limitations Questionnaire (WLQ; p<0.0001) indicated improvements in the effects of patients' symptoms on functioning (work/school, social life, and home responsibilities). Changes from baseline in additional measures supported improvements in patient functioning and depression symptoms. The most common adverse events were headache (21.3%), weight increase (17.0%), and somnolence (17.0%); reported rates of akathisia were low (6.4%). Clinically relevant increases in weight (≥7%) occurred in 10.5% of patients. LIMITATIONS: Open-label design; absence of comparator. CONCLUSIONS: Brexpiprazole may represent an effective therapy for adjunctive treatment strategy of young adults with MDD who are working or studying. The observed improvements in work/school functioning in patients with MDD, whose depression was treated with ADT+brexpiprazole, suggests potential to reduce socioeconomic burden.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Affect Disord

DOI

EISSN

1573-2517

Publication Date

November 1, 2016

Volume

204

Start / End Page

40 / 47

Location

Netherlands

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Thiophenes
  • Students
  • Quinolones
  • Psychiatry
  • Psychiatric Status Rating Scales
  • Male
  • Humans
  • Follow-Up Studies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Weisler, R. H., Ota, A., Tsuneyoshi, K., Perry, P., Weiller, E., Baker, R. A., & Sheehan, D. V. (2016). Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. J Affect Disord, 204, 40–47. https://doi.org/10.1016/j.jad.2016.06.001
Weisler, Richard H., Ai Ota, Kana Tsuneyoshi, Pamela Perry, Emmanuelle Weiller, Ross A. Baker, and David V. Sheehan. “Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment.J Affect Disord 204 (November 1, 2016): 40–47. https://doi.org/10.1016/j.jad.2016.06.001.
Weisler RH, Ota A, Tsuneyoshi K, Perry P, Weiller E, Baker RA, et al. Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. J Affect Disord. 2016 Nov 1;204:40–7.
Weisler, Richard H., et al. “Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment.J Affect Disord, vol. 204, Nov. 2016, pp. 40–47. Pubmed, doi:10.1016/j.jad.2016.06.001.
Weisler RH, Ota A, Tsuneyoshi K, Perry P, Weiller E, Baker RA, Sheehan DV. Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. J Affect Disord. 2016 Nov 1;204:40–47.
Journal cover image

Published In

J Affect Disord

DOI

EISSN

1573-2517

Publication Date

November 1, 2016

Volume

204

Start / End Page

40 / 47

Location

Netherlands

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Thiophenes
  • Students
  • Quinolones
  • Psychiatry
  • Psychiatric Status Rating Scales
  • Male
  • Humans
  • Follow-Up Studies